Repare Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Repare Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Repare Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Repare Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Repare Therapeutics Inc (Repare Therapeutics), a subsidiary of XenoTherapeutics Inc, is a clinical-stage precision oncology company that focuses on developing targeted therapies that address genetic alterations in tumors. It carries out leveraging its proprietary SNIPRx platform to discover and develop synthetic lethality-based therapeutics. The company's products include lunresertib, a PKMYT1 inhibitor, camonsertib, an ATR inhibitor, RP-1664, a PLK4 inhibitor, and RP-3467, a Polo ATPase inhibitor. Repare Therapeutics' products are primarily aimed at patients with specific genetic alterations in their tumors, applicable across various oncology sectors. The company operates in the US and Canada. Repare Therapeutics is headquartered in Montreal, Quebec, Canada.
Headquarters
Canada
Address
7210 Frederick-Banting, Suite 100, St. Laurent, Quebec, H4S2A1
Website
www.reparerx.com
No of Employees
129
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$53.5M
Repare Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | SNIPRx |
| Lunresertib: Cancer | |
| Camonsertib: Cancer | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Ownership Changes | In January, the company was acquired by XenoTherapeutics Inc and Xeno Acquisition Corp. |
| 2025 | Contracts/Agreements | In December, the company signed an agreement to sell polymerase theta (Polθ) ATPase inhibitor, RP-3467 to Gilead Sciences Inc. |
| 2025 | Contracts/Agreements | In July, the company signed a licensing agreement with Debiopharm International for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. |
Competitor Comparison
| Key Parameters | Repare Therapeutics Inc | Pfizer Inc | GSK plc | Exelixis Inc | Blueprint Medicines Corp |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | United Kingdom | United States of America | United States of America |
| City | St. Laurent | New York City | London | Alameda | Cambridge |
| State/Province | Quebec | New York | England | California | Massachusetts |
| No. of Employees | 129 | 75,000 | 66,841 | 1,077 | 682 |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Steve Forte | Chief Financial Officer; Director; Executive Vice President; President | Executive Board | 2019 | 46 |
| Sandra Alves | Chief Accounting Officer; Senior Vice President | Senior Management | 2025 | - |
| Michael Zinda, Ph.D. | Chief Scientific Officer; Executive Vice President | Senior Management | 2019 | 54 |
| Philip Herman | Chief Commercial and Portfolio Development Officer; Executive Vice President | Senior Management | 2022 | - |
| Daniel Bélanger | Executive Vice President - Human Resources | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer